Form 4: Vickers Venture Fund VI Pte Ltd Reports Conversion of Preferred Stock into Common Stock Following Aardvark Therapeutics IPO
SEC Filing Form 4
Vickers Venture Fund VI Pte Ltd reports the conversion of Series A and B Convertible Preferred Stock into common stock following Aardvark Therapeutics' initial public offering.
Summary
- Vickers Venture Fund VI Pte Ltd has filed a Form 4 with the SEC.
- The filing reports the conversion of Series A and Series B Convertible Preferred Stock into common stock of Aardvark Therapeutics, Inc. (AARD).
- The conversions occurred on February 14, 2025, immediately prior to the closing of Aardvark Therapeutics' IPO.
- 1,637,411 shares of common stock were obtained from the conversion of Series A Preferred Stock.
- 413,491 shares of common stock were obtained from the conversion of Series B Preferred Stock.
- Following the reported transactions, Vickers Venture Fund VI Pte Ltd beneficially owns 2,050,902 shares of common stock indirectly.
- The shares are held directly by Vickers Venture Fund VI Pte. Ltd.
- Vickers Venture Global Deep-tech Fund II (EU) SCSP-RAIF and Vickers Venture Global Deep-tech Fund II (CI) L.P. are the sole shareholders of Vickers Fund VI.
- Dr. Jeffrey Chi, a member of Aardvark Therapeutics' Board of Directors, is among those who collectively exercise shared voting and dispositive power over the securities held by Vickers Fund VI.
Sentiment
Score: 7
Explanation: The document is a routine SEC filing related to an IPO, indicating a completed transaction. The sentiment is neutral to slightly positive as it reflects a company achieving a significant milestone.
Industry Context
This filing is a standard procedure following an IPO, as preferred stock typically converts to common stock upon the company going public. It reflects the ownership structure and changes resulting from the IPO event.
Stakeholder Impact
- The conversion of preferred stock to common stock impacts shareholders by increasing the number of outstanding common shares.
- This event is a standard part of the IPO process and generally expected by investors.
Key Dates
| Date | Description |
|---|---|
| 02/14/2025 | Date of conversion of Series A and B Convertible Preferred Stock to Common Stock. |
| 02/19/2025 | Date of signature of the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.